Related Experiment Video
Updated: Jun 14, 2026
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Folate conjugated poly(ester amine) for lung cancer therapy
Rohidas B Arote1, Mi-Kyong Yoon, Tae-Hee Kim
1School of Agricultural Biotechnology, Seoul National University, Seoul 151-921, Korea.
Journal of Nanoscience and Nanotechnology
|April 3, 2010
Summary
Researchers developed a novel folate-conjugated poly(ester amine) gene carrier. This advanced material exhibits superior physicochemical properties and transfection efficiency, offering a promising alternative to traditional carriers.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Gene Delivery Systems
Background:
- Poly(ester amine)s (PEAs) are investigated as non-viral gene vectors.
- Polyethylenimine (PEI) is a common gene carrier but exhibits toxicity.
- Targeted delivery can enhance gene carrier efficacy and reduce side effects.
Purpose of the Study:
- To synthesize and characterize novel folate-conjugated poly(ester amine) (PEA) gene carriers.
- To evaluate the physicochemical properties, cytotoxicity, and transfection efficiency of the developed PEA.
- To investigate the potential of folate receptor-mediated endocytosis for targeted gene delivery.
Main Methods:
- Folate conjugation to PEAs synthesized from polycaprolactone (PCL) and low molecular weight polyethylenimine (LMW-PEI) using PEG as a linker.
- Assessment of physicochemical properties (e.g., size, charge).
- In vitro cytotoxicity assays and gene transfection efficiency studies.
Main Results:
- The novel folate-conjugated PEA demonstrated excellent physicochemical properties.
- The gene carrier exhibited significantly lower cytotoxicity compared to PEI 25K.
- High transfection efficiency was observed, attributed to folate receptor-mediated endocytosis.
Conclusions:
- Folate-conjugated PEA represents a promising, low-cytotoxicity gene delivery system.
- Targeting folate receptors enhances gene delivery efficacy.
- This approach offers a potential advancement in targeted non-viral gene therapy.
More Related Videos
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...